Table 2 The model reduction and the partial likelihood ratio (LR) test revealed that a baseline model with the novel risk groups is statistically comparable to the full model to predict cancer-specific survival.
Model | Nested partial likelihood ratio test, LR (p-value) | AIC | BIC |
|---|---|---|---|
1st external validation set (CPCBN) | |||
Baseline model + risk group + GG | Reference (full model) | 167.5161 | 169.6403 |
Baseline model + risk group | 1.560 (0.213) | 167.07 | 168.4861 |
Baseline model + GG | 4.114 (0.036) | 169.6098 | 171.0259 |
Baseline model (pT) | 7.557 (0.027) | 171.0623 | 171.7703 |
2nd external validation set (PROCURE) | |||
Baseline model + risk group + GG | Reference (full model) | 170.6459 | 174.824 |
Baseline model + risk group | 4.094 (1.2e−1) | 172.7398 | 175.8733 |
Baseline model + GG | 10.056 (1.8e−3) | 178.7017 | 181.8353 |
Baseline model (pT + pN) | 27.777 (6.8e−5) | 194.4228 | 196.5119 |
3rd external validation set (PLCO)a | |||
Baseline model + risk group + GS | Reference (full model) | 298.0581 | 301.8323 |
Baseline model + risk group | 14.849 (1e−4) | 310.9075 | 313.4237 |
Baseline model + GS | 5.15 (0.023) | 301.2158 | 303.732 |
Baseline model (prostate pathologic stage) | 26.769 (1.54e−06) | 320.8274 | 322.0855 |